Surya Singh's guest appearances

Surya Singh

The ShiftShapers Podcast

HealthBiz with David E. Williams

Sanjay Prasad

Ashok Subramanian

Justin Davis

Larry Diamond

Alan Cohen

Andrew Parker

Tom Scott

Michael Walsh

Michael Zipursky

Brian Clarke

Blake Richards

Josh Butler

Mike Rea

Ryan Miller

Amy Brown

OwlTail

This week’s episode features a conversation with Surya Singh, CEO and Co-founder at gWell. Muskoskeletal claims are growing monster that gobbles up claims spends. Cutting-edge tech in genomics, AI, and machine learning help create diagnostics for the best treatments since many chronic conditions have genetic markers associated with them. At the same time, this technology cuts costs by as much as a third of current spends, a significant percentage that's of interest to employers and patients alike.What You’ll Learn From This Episode:01:57 Surya’s professional background03:44 Musculoskeletal claims: Rising costs associated with longer lives06:14 Genomics and genetics help diagnose chronic conditions13:46 AI and machine learning accurately determine the recovery time of patients18:46 Genetic testing and genomics cut overall spend by a thirdQuotes:05:06 “People are surviving longer and so after you get that first knee surgery, arthroscopic knee procedure, even a knee replacement or hip replacement, you may outlive it. You may live long enough that you need another one now.”08:41 “For almost every common chronic disease or condition that develops, there are multiple genes at play. And not only are there multiple genes at play, those genes are expressed, they are used, in different combinations and at different levels by the body.”15:39 “We can understand which of those pathways are the ones that are leading to better form and function, leading to better phenotypic outcomes for people. Artificial intelligence and machine learning are a way to be able to do that.”18:22 “Which genetic markers that dictate whether or not they respond well to e-centric exercise, the weight-bearing exercise, and how long their recovery periods are in between can really help dictate are they out from being functional again for 2 weeks or a month or 6 months.”20:30 “One thing I worry about in terms of making sure that the impact is as broad as it can be in terms of economics and in terms of value, and also to use another little cliche that’s used a lot now, that no one is left behind so to speak.”

This week’s episode features a conversation with Surya Singh, CEO and Co-founder at gWell. Muskoskeletal claims are growing monster that gobbles up claims spends. Cutting-edge tech in genomics, AI, and machine learning help create diagnostics for the best treatments since many chronic conditions have genetic markers associated with them. At the same time, this technology cuts costs by as much as a third of current spends, a significant percentage that's of interest to employers and patients alike.What You’ll Learn From This Episode:<ul><li>01:57 Surya’s professional background</li><li>03:44 Musculoskeletal claims: Rising costs associated with longer lives</li><li>06:14 Genomics and genetics help diagnose chronic conditions</li><li>13:46 AI and machine learning accurately determine the recovery time of patients</li><li>18:46 Genetic testing and genomics cut overall spend by a third</li></ul>Quotes:05:06 “People are surviving longer and so after you get that first knee surgery, arthroscopic knee procedure, even a knee replacement or hip replacement, you may outlive it. You may live long enough that you need another one now.”08:41 “For almost every common chronic disease or condition that develops, there are multiple genes at play. And not only are there multiple genes at play, those genes are expressed, they are used, in different combinations and at different levels by the body.”15:39 “We can understand which of those pathways are the ones that are leading to better form and function, leading to better phenotypic outcomes for people. Artificial intelligence and machine learning are a way to be able to do that.”18:22 “Which genetic markers that dictate whether or not they respond well to e-centric exercise, the weight-bearing exercise, and how long their recovery periods are in between can really help dictate are they out from being functional again for 2 weeks or a month or 6 months.”20:30 “One thing I worry about in terms of making sure that the impact is as broad as it can be in terms of economics and in terms of value, and also to use another little cliche that’s used a lot now, that no one is left behind so to speak.”

Ep# 360:  Taming "The Other" Claims Cost Monster - with Surya Singh

Wouldn’t it be great if remdesivir magically cured COVID-19? Too bad it doesn’t. So what should we be willing to pay for a drug that shortens hospital stays and might reduce mortality? In this episode of HealthBiz, physician and healthcare executive Surya Singh shares his take on drug pricing, ICER and the future of the pandemic. Check out the links.Surya’s LinkedIn profile https://www.linkedin.com/in/surya-singh-8540032/ Institute for Clinical and Economic Review (ICER) remdesivir pricing model https://icer-review.org/announcements/alternative_pricing_models_for_remdesivir/ Letter from State Attorneys General about remdesivir pricing https://patreasury.gov/pdf/newsroom/Gilead-Sciences-Letter_Redacted.pdf Boston Globe article comparing MA and RI school reopening plans https://www.bostonglobe.com/2020/09/18/metro/how-rhode-island-brought-most-students-back-in-person-learning-massachusetts-did-not/ Remdesivir https://www.gilead.com/remdesivir Inspiration for “Remdesivir powers, activate!” https://youtu.be/FouDjI3GzEI David’s LinkedIn profile https://www.linkedin.com/in/davideugenewilliams/ Health Business Group https://healthbusinessgroup.com/ Support the showHost David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

Wouldn’t it be great if remdesivir magically cured COVID-19? Too bad it doesn’t. So what should we be willing to pay for a drug that shortens hospital stays and might reduce mortality? In this episode of HealthBiz, physician and healthcare executive Surya Singh shares his take on drug pricing, ICER and the future of the pandemic.  Check out the links.<ul><li>Surya’s LinkedIn profile <a href="https://www.linkedin.com/in/surya-singh-8540032/" rel="nofollow" target="_blank">https://www.linkedin.com/in/surya-singh-8540032/</a> </li><li>Institute for Clinical and Economic Review (ICER) remdesivir pricing model <a href="https://icer-review.org/announcements/alternative_pricing_models_for_remdesivir/" rel="nofollow" target="_blank">https://icer-review.org/announcements/alternative_pricing_models_for_remdesivir/</a> </li><li>Letter from State Attorneys General about remdesivir pricing <a href="https://patreasury.gov/pdf/newsroom/Gilead-Sciences-Letter_Redacted.pdf" rel="nofollow" target="_blank">https://patreasury.gov/pdf/newsroom/Gilead-Sciences-Letter_Redacted.pdf</a> </li><li>Boston Globe article comparing MA and RI school reopening plans <a href="https://www.bostonglobe.com/2020/09/18/metro/how-rhode-island-brought-most-students-back-in-person-learning-massachusetts-did-not/" rel="nofollow" target="_blank">https://www.bostonglobe.com/2020/09/18/metro/how-rhode-island-brought-most-students-back-in-person-learning-massachusetts-did-not/</a> </li><li>Remdesivir <a href="https://www.gilead.com/remdesivir" rel="nofollow" target="_blank">https://www.gilead.com/remdesivir</a> </li><li>Inspiration for “Remdesivir powers, activate!” <a href="https://youtu.be/FouDjI3GzEI" rel="nofollow" target="_blank">https://youtu.be/FouDjI3GzEI</a> </li><li>David’s LinkedIn profile <a href="https://www.linkedin.com/in/davideugenewilliams/" rel="nofollow" target="_blank">https://www.linkedin.com/in/davideugenewilliams/</a> </li><li>Health Business Group <a href="https://healthbusinessgroup.com/" rel="nofollow" target="_blank">https://healthbusinessgroup.com/</a> </li></ul><a href="https://www.buzzsprout.com/1367974/support" rel="payment nofollow" target="_blank">Support the show</a>Host <a href="https://www.linkedin.com/in/davideugenewilliams/" rel="nofollow" target="_blank">David E. Williams</a> is president of healthcare strategy consulting firm <a href="https://www.healthbusinessgroup.com/" rel="nofollow" target="_blank">Health Business Group</a>. Produced by <a href="https://www.linkedin.com/in/dafna-williams-53aaa7199/" rel="nofollow" target="_blank">Dafna Williams</a>.

Remdesivir powers, activate! Surya Singh